

LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DEANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND*
MICHAEL PHILLIPS*
LISA M. DIROCCO
HATHAWAY P. RUSSELL **
MARIA LACCOOTRIPE ZACHARAKIS, Ph.D.
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

0590
12/12
PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFIELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. MCPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

May 31, 2002

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/994,425
TARGETED DELIVERY OF GENES ENCODING INTERFERON
Inventor: Henry C. Chiou *et al.*
Filed: November 26, 2001
Our Ref. No.: TTI-143CPCN2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. A Return Postcard.


No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

May 31, 2002
Date

Jane E. Remillard, Reg. No. 38,872

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Jane E. Remillard
Registration No. 38,872
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Henry C. Chiou *et al.*

Serial No.: 09/994,425

Filed: November 26, 2001

For: **TARGETED DELIVERY OF GENES
ENCODING INTERFERON**

Attorney Docket No.: TTI-143CPCN2

Group Art Unit:

Examiner:

Commissioner for Patents
Washington, D.C. 20231


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

May 31, 2002

Date of Signature and of Mail Deposit

By:


Jane E. Remillard
Registration No. 38,872
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


For the Examiner's convenience in reviewing this continuation application, Applicant submits a consolidated PTO Form 1449, listing all references cited during the prosecution of the parent application. The present application is a continuation of U.S. Serial No.09/379,434, filed August 23, 1999 (Atty. Docket No. TTI-143CPCN). All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of the of the references are not enclosed but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Jane E. Remillard
Registration No. 38,872
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: May 31, 2002

GAD/JER/RKN/ ipc

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TTI-143CPCN2	SERIAL NO. 09/994,425
JC 47 LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Henry C. Chiou et al.	
		FILING DATE November 26, 2001	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,166,320	11/92	Wu et al.	530	395	
	A2	5,346,696	09/94	Kim et al.	424	85.4	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	A3	WO 92/19749	11/92	PCT			
	A4	WO 92/22310	12/92	PCT			
	A5	WO 92/22635	12/92	PCT			
	A6	WO 93/07283	04/93	PCT			
	A7	WO 93/15609	08/93	PCT			
	A8	WO 94/06922	03/94	PCT			
	A9	1 111 159	11/95	China			


OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A10	Abstract from the Second Annual Industry Congress on Hepatitis, entitled "Receptor-Mediated Delivery of Therapeutic Agents for Treatment of Chronic HBV Infections", Bartholomew, R.M., (circulated in January, 1996)
A11	Baron, S. and F. Dianzani (1994), "The interferons: A biological system with therapeutic potential in viral infections", <i>Antivir. Res.</i> 24 :97-110
A12	Baron, S. et al. (1991), "The Interferons: Mechanisms of Action and Clinical Applications," <i>JAMA</i> 266 :1375-1383
A13	Coll, et al., "In Vitro Targeting and Specific Transfection of Human Neuroblastoma Cells by chCE7 Antibody-Mediated Gene Transfer", <i>Gene Therapy</i> , Abstract provided by the PCT, Vol. 4 (2), pp. 156-161 (1997);
A14	"Drug Facts and Comparisons", 1992 Edition, eds. Olin, B.R. et al., St. Louis, MO, pp. 2445-2460
A15	Gwertz, D. et al. (1993), "Analysis of Interferon- α 2 Sequences in Human Genomic DNA," <i>Journal of Interferon Research</i> 13 :227-231
A16	Hodgson, C. (1995), "Advances in Vector Systems for Gene Therapy," <i>Exp. Opin. Ther. Patents</i> 5 :459-468
A17	Miller, N. and Vile, R. (1995), "Targeted Vectors for Gene Therapy," <i>FASEB J.</i> 9 :190-199
A18	Mulligan, R. (1993), "The Basic Science of Gene Therapy," <i>Science</i> 260 :926-930

Examiner _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. TTI-143CPCN2	SERIAL NO. 09/994,425
LIST OF PUBLICATIONS CITED BY APPLICANT (use several sheets if necessary)		APPLICANT Henry C. Chiou et al.	
		FILING DATE November 26, 2001	GROUP



U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

B1	O'Malley, B. and Ledley, F. (1993), "Somatic Gene Therapy," <i>Arch Otolaryngol Head Neck Surg.</i> 119 :1100-1107
B2	Orkin, S. and Motulsky, A. (1995), "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy."
B3	Perrillo et al., "A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B," <i>New England J. of Med.</i> , 323 :295-301
B4	Slocombe, P. et al. (1982), "High-level Expression of an Interferon α 2 Gene Cloned in Phage M13mp7 and Subsequent Purification with a Monoclonal Antibody," <i>Proc. Natl. Acad. Sci. USA</i> 79 :5455-5459
B5	Streuli et al., "At least three human type alfa interferons; Structure of alfa2," <i>Science</i> , 209 :1343-1347
B6	Wu, C.H. et al. (1989), "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements <i>in Vivo</i> ," <i>J. Biol. Chem.</i> 264 :16985-16987
B7	Wu, G.Y. and C.H. Wu (1988), "Receptor-mediated Gene Delivery and Expression <i>in Vivo</i> ," <i>The Journal of Biological Chemistry</i> 263 :14621-14624
B8	Wu, G.Y. and C.H. Wu (1987), "Receptor-mediated <i>in Vitro</i> Gene Transformation by a Soluble DNA Carrier System," <i>J. Biol. Chem.</i> 262 :4429-4432
B9	Wu, G.Y. et al. (1991), "Receptor-mediated Gene Delivery <i>in Vivo</i> ," <i>The Journal of Biological Chemistry</i> 266 :14338-14342

Examiner	Date Considered
----------	-----------------

*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
------------	--